Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism

Horm Metab Res. 1998 Oct;30(10):642-5. doi: 10.1055/s-2007-978950.

Abstract

Background: Excessive testosterone in males or estrogens in females could explain their differences in coronary heart disease event rates. As a contraceptive testosterone is likely to be used at large scale the role of testosterone in increasing the risks of coronary heart disease needs investigation.

Aim: To look at the role of testosterone in development of insulin resistance and other cardiovascular risk factors.

Design: Prospective, before-after study on ten male subjects with idiopathic hypogonadotrophic hypogonadism pre- and post-testosterone replacement therapy; outcome measures: anthropometry, lipoprotein profile and M value (whole body glucose disposal rates on standard hyperinsulinemic euglycemic clamp; at insulin infusion rate: 40 mU x (m-2)).

Results: Pre-treatment serum testosterone was 0.43 (0.515) ng x mL(-1), LH was 1.29 (0.08) IU x L(-1), and FSH was 1.54 (0.08) IU x L(-1). None had glucose intolerance. After replacement testosterone levels increased to 9.4 ng x mL(-1) (p=0.0005); weight increase of 5.0 kg (p=0.140), body mass index increase of 1.2 kg x m(-2) (p=0.28), and the change in waist to hip ratio (p=0.31) were not statistically significant. M-value (mg x kg x min(-1)) did not change after testosterone therapy (5.86 [0.72] vs 5.29 [0.82], p=0.62). Insulin levels (mU x L(-1)) achieved during the clamps were 89.5 (14.2) before and 146 (32.2) after androgen therapy (p=0.127). There was no change in glucose area under curve (mg x min x dL(-1)) (14406 [502.2] vs 12557 [826.5], p=0.312). On testosterone replacement therapy total and LDL cholesterol levels (mg x dL(-1)) declined (122.5 [13.4] vs 91.6 [5.0], p=0.04; 65.9 [9.9] vs 39.4 [7.3], p=0.05); Ratio of total cholesterol to HDL ratio also decreased significantly (p=0.05). Changes of serum triglycerides (p=0.25) and HDL cholesterol (p=0.19) did not attain statistical significance.

Conclusions: Insulin sensitivity does not decrease on testosterone replacement therapy of male subjects with idiopathic hypogonadotrophic hypogonadism. Testosterone replacement was associated with decrease in other cardiovascular risk factors.

MeSH terms

  • Adult
  • Blood Glucose / metabolism*
  • Body Constitution
  • Body Mass Index
  • Cardiovascular Diseases / chemically induced*
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Follicle Stimulating Hormone / blood
  • Glucose Clamp Technique
  • Glucose Tolerance Test
  • Humans
  • Hypogonadism / drug therapy*
  • Insulin Resistance*
  • Luteinizing Hormone / blood
  • Male
  • Prospective Studies
  • Risk Factors
  • Testosterone / adverse effects*
  • Testosterone / blood
  • Testosterone / therapeutic use
  • Triglycerides / blood

Substances

  • Blood Glucose
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Triglycerides
  • Testosterone
  • Luteinizing Hormone
  • Follicle Stimulating Hormone